2024-04-25
PinkDx public launch
PinkDx’s launch announcement identified Kennedy as co-founder and Chief Scientific Officer. This is a public-documentation date, not a founding-date claim.
View the source04 / 04 · Co-founder & Chief Scientific Officer
A new question for women’s health
At PinkDx, Kennedy leads scientific strategy and translational research focused on gynecologic cancer.
← Back to the career genomeA sourced chapter
The work in context.
PinkDx identified Kennedy as co-founder and Chief Scientific Officer at its April 2024 public launch. A 2026 exploratory paper, coauthored by Kennedy, reported molecular signals of endometrial cancer in vaginal swabs. The preliminary analysis does not establish a clinically validated test or a routine screening pathway; a subsequent study is intended to evaluate the approach.
Could a less invasive sample yield enough molecular information to inform a diagnostic pathway?
Documented milestones, not claimed outcomes
On the record.
2026-04
Exploratory endometrial-cancer paper published
Coauthored proof-of-concept paper on RNA signals in vaginal swabs; the sample and design limit clinical interpretation.
View the sourceResearch linked to this period
Connected questions.
Transcriptomics & classification
RNA-sequencing and machine-learning methods used to investigate diagnostic questions.
Explore the areaEndometrial cancer research
Exploratory evidence for molecular signals in vaginal swabs; clinical validation remains necessary.
Explore the areaSelected coauthored work
Published evidence.
2026
Whole-transcriptome sequencing and machine learning detect molecular signatures of endometrial cancer in non-invasive vaginal swabs
Context: Preliminary subset analysis; not evidence of a clinically validated screening or diagnostic test.
What the evidence can say
The boundary matters.
The 2026 study is exploratory proof of concept, not a clinically validated test, general-population screening method or replacement for biopsy. A subsequent study is intended to evaluate the approach.
Documented relationships
People & institutions on record
A line here means a recorded role, training or publication affiliation. It does not infer a permanent team or employment from coauthorship.
- Co-founderGiulia C. KennedyPinkDx
Co-founder and Chief Scientific Officer · Documented at public launch 2024-04-25; exact start date unknown
View record - Co-founderBonnie AndersonPinkDx
Co-founder, Chair and CEO
View record - Co-founderTim McMeekanPinkDx
Co-founder, CFO and CBO at launch
View record - Affiliation on cited publicationJason D. WrightColumbia University Irving Medical Center
2026 paper coauthor affiliation
View record - Affiliation on cited publicationPedro T. RamirezHouston Methodist Hospital
2026 paper coauthor affiliation
View record - Affiliation on cited publicationAndrea MarianiMayo Clinic
2026 paper coauthor affiliation
View record
Chapter sources
Evidence is linked to its original record. Dates and interpretations are qualified in the chapter text.
- PinkDx launches with $40 million Series A financing PinkDx · 2024-04-25
- PinkDx team biographies PinkDx
- Whole-transcriptome sequencing and machine learning detect molecular signatures of endometrial cancer in non-invasive vaginal swabs International Journal of Gynecological Cancer · 2026-04
- PinkDx publishes evidence in endometrial cancer detection PinkDx · 2026-04-06